PRNews

European Patent Office to Grant Merck’s Patent Application for CRISPR Technology

– Patent application covers integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR

– Related patent application recently awarded in Australia; similar patents pending in other countries, favourable outcomes anticipated

DARMSTADT, Germany, Aug. 3, 2017 /PRNewswire/ — Merck, a leading science and technology company, today announced the European Patent Office (EPO) has issued a “Notice of Intention to Grant” for Merck’s patent application covering the company’s CRISPR technology used in a genomic integration method for eukaryotic cells.


Merck’s patent application covers integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR. The patent will give Merck’s CRISPR genomic integration technology broad protection, further strengthening the company’s patent portfolio.

The patent will provide Merck’s CRISPR genomic integration technology with broad protection, further strengthening the company’s patent portfolio. A related patent was approved in Australia in June 2017.  Merck anticipates favourable outcomes in other countries as well, because many patent offices worldwide consider the status of related European cases to be highly relevant to the decision to grant patents.

“This is a significant and exciting decision by the EPO, and we view this announcement as recognition of Merck’s important contributions to the genome-editing field,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “This patent provides protection for our CRISPR technology, which will give scientists the ability to advance treatment options for the toughest medical challenges we face today.”

With Merck’s CRISPR genomic integration technology, scientists can replace a disease-associated mutation with a beneficial or functional sequence – a method important for creation of disease models and gene therapy. Scientists can also use the method to insert transgenes to enable basic research, using the technology to label endogenous proteins for visual tracking within cells, for example.

This patent application is one of Merck’s multiple CRISPR patent filings since 2012. In May 2017, Merck introduced an alternative CRISPR genome-editing method called proxy-CRISPR. Unlike other systems, the proxy-CRISPR technique allows cutting of previously unreachable cell locations, making CRISPR more efficient, flexible and specific—giving researchers more experimental options.

Merck, with its 14-year history in the genome-editing field, was the first company to offer custom biomolecules globally for genome editing (TargeTron™ RNA-guided group II introns and CompoZr™ zinc finger nucleases), driving widespread adoption by researchers. In collaboration with the Wellcome Trust Sanger Institute, Merck was also the first company to manufacture arrayed CRISPR libraries covering the entire human genome, allowing researchers to explore more questions about disease and develop cures faster. Availability of arrayed CRISPR libraries is an important advancement in genome editing and reinforces the company’s leadership position.

The company also supports development of gene- and cell-based therapeutics and manufactures viral vectors, in addition to conducting basic genome-editing research. In 2016, Merck launched an initiative to advance research in novel treatment modalities, from genome editing to gene medicine manufacturing, through a dedicated team and enhanced resources. This venture further solidifies the company’s commitment to the genome-editing field.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.

Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

PRNews

Frost & Sullivan Acclaims Shimadzu for Delivering a Product Line of Versatile and Innovative Radiography Solutions

Shimadzu’s products utilize advanced robotic capabilities and next-generation digital imaging technologies

LONDON, Aug. 3, 2017 /PRNewswire/ — Based on its recent analysis of the general radiography market, Frost & Sullivan recognizes Shimadzu Corporation with the 2017 Global Frost & Sullivan Award for Product Line Strategy Leadership. Constant innovations and upgrades to Shimadzu’s radiography product portfolio have ensured that the products stay relevant and in high demand in an evolving radiography market. Its comprehensive product range enhances automation, efficiency, image quality, and overall clinical value by enabling flexible positioning, reduced radiation dose, and versatility in viewing bone and soft tissue images.

Shimadzu has the entire range of general radiography solutions, from fixed ceiling-mounted to floor-mounted systems and mobile X-ray solutions, with or without one to two arms. These are all available all in entry-level to high-end configurations. In 2016, it introduced new technologies such as digital multi-slice tomography with flexible positioning to offer a view of oblique cross sections of the spine and hip joints. Other products include:

  • SONIALVISION G4, a fluoroscopy product with multi-functionality features
  • RADspeed Pro EDGE package, a high-performance general radiography equipment
  • MobileDaRt Evolution MX7 Version, mobile X-ray with digitization features.

RADspeed Pro EDGE and MobileDaRt Evolution MX7 have already been adopted by more than 100 hospitals worldwide within a year of their introduction.

“In response to customer demand, Shimadzu introduced a sophisticated, remote-controlled, auto-positioning feature in the RADspeed Pro EDGE package. This feature helps the radiographer effortlessly position the tube and fine-tune this positioning to improve patient safety and reduce radiation dose,” said Frost & Sullivan Consultant Poornima Srinivasan. “Similarly, it incorporated removable grids to lower radiation exposure during pediatric imaging, and a dose area product meter on the collimator to measure the dose of radiation the patient is exposed to.”

Shimadzu’s products have proven their utility in guiding hospitals towards the era of value-based healthcare. They achieve that by incorporating a host of novel features and technologies.

  • The RADspeed Pro EDGE employs cutting-edge technologies like tomosynthesis, speed stitch, and dual energy subtraction. Tomosynthesis combines cone-beam computed tomography (CT) reconstruction with digital image processing so that any number of cross-sectional images can be obtained. The systems also incorporate ‘T-smart,’ the metal artifact reduction technology that decreases metal artifacts in orthopedic patients. Additionally, it uses speed stitch technology, which combines multiple images that are captured while the X-ray tube is in motion at various angles. Finally, its dual energy subtraction, imaging algorithm, couples with low and high voltages to offer images of soft tissue and bone images separately.
  • SONIALVISION G4 is capable of a wide range of examinations and is ideal for inter-departmental shared services. The field of view (FOV) flat panel detector (FPD) is available in five sizes and provides an extensive imaging area, ultra-high definition and dynamic images, less radiation exposure, a ceiling-mounted telescopic arm, and a wall stand with a portable FPD. It incorporates technologies such as:
    • The SUREengine-Advance, an image processing technology that delivers quality fluoro and radiography images
    • SLOT Advance, an optimal technology for long-view images with a minimal X-ray dose
    • T-smart, the latest tomosynthesis technology that aids in iterative reconstruction with metal artifact suppression
  • The MobileDaRt Evolution MX7 Version incorporates a large LCD monitor and LED collimator light that increases brightness up to 40% and saves electricity by 80% when compared to its competing products. It also has a user-friendly design with wireless capability, which allows it to extend its scope of application.

“Shimadzu has leveraged the expertise of key opinion leaders (KOLs), designed training and educational programs, expanded geographically, and made the most of cross-selling opportunities in line with its business goals,” noted Ms. Srinivasan. “Additionally, it has partnered with universities to optimize the existing systems and develop further innovations and efficiencies. Shimadzu’s discussions with international channels, and focus on gathering input from healthcare professionals have played a huge role in its development of unique products and provision of a rich customer experience.”

Each year, Frost & Sullivan presents this award to the company that has developed a comprehensive product line that caters to the breadth of the market it serves. The award recognizes the extent to which the product line meets customer base demands, the overall impact it has in terms of customer value, as well as increased market share.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Shimadzu Corporation

Shimadzu Corporation has remained committed to commercializing cutting-edge technology and providing it to customers in a wide array of industries for more than 140 years. Our brand statement, “Excellence in Science”, reflects our desire and attitude to diligently respond to customers’ requirements by offering superior, world-class technologies indispensable for analytical and measuring instruments, medical systems, aircraft equipment and industrial machinery in the area of human health, safety and security of society and advancement of industry. In the ever-changing landscape of challenges of society, Shimadzu aims to partner with customers to meet their needs with unique technologies and solutions.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Ana Arriaga
P: 210.247.3823
F: 210.348.1003
E: ana.arriaga@frost.com

PRNews

A Delegation led by Director Li Weimin of West China Hospital, Sichuan University Visited the UK

CHENGDU, China, Aug. 2, 2017 /PRNewswire/ — On July 9-14 this year, a delegation led by director Li Weimin of West China Hospital, Sichuan University visited University of Liverpool, Cambridge University Hospitals, and Imperial College London in the UK. The delegation consisted of representatives from multiple departments and divisions of West China Hospital, Sichuan University, including Integrated TCM & Western Medicine Department, Cardiac Surgery Department, Anesthesiology Department, Health Care Division, Biological Specimen Bank, Information Center, and International Exchange and Cooperation Office.


Prof. Li Weimin of West China Hospital signed a cooperation with Takis Kotis, CEO of UKeMED Platform of Cambridge University

While at University of Liverpool, the delegation visited its core medical research departments including Clinical Research Center, Research Accelerator, North West Cancer Research Centre, Biobank, Institute of Integrative Biology, and Institute of Translational Medicine, and held discussions with the host about potential cooperation in the field of biomedical research in the future.

On July 10, a bilateral cooperation forum was organized, and leaders and experts from University of Liverpool and Royal Liverpool University participated. In this forum, director Li Weimin reviewed the cooperation history between University of Liverpool and West China Hospital, stating that University of Liverpool had cultivated nearly ten talents for West China Hospital and that reinforced cooperation would greatly benefit both parties due to their traditional focus on scientific research. Executive vice director Wan Xuehong gave an overview of West China Hospital, and recommended further cooperation plans with regard to doctor and post-doctor cultivation, expert exchange, and joint establishment of West China Liverpool Biomedicine Research Center and Liverpool West China Center. After the forum, director Li Weimin signed a Liverpool – West China cooperation memorandum with Bob Burgoyne, executive pro-vice-chancellor of University of Liverpool and dean of Faculty of Health and Life Sciences.

While at Cambridge University, the delegation met the managers of remote medical platform UKeMED, and communicated with representatives from institutes such as Cambridge University Hospitals and University of Bedfordshire. The delegation also made a video presentation about world leading medical technologies of West China Hospital. After the meeting, director Li Weimin and Takis Kotis, CEO of UKeMED Platform, signed a cooperation memorandum concerning remote medicine and education as well as a letter of intent for cooperation under The Belt and Road initiative.

On the afternoon of July 12, the delegation met Roland Sinker, CEO of Cambridge University Hospitals. Later, the delegation paid a visit to Biomedical Research Centre (BRC) Of Cambridge University, during which discussions were held with experts of the centre about challenges confronted by West China Hospital in biomedical research.

During their stay in London, the delegation visited Health care UK (HCUK). Ms. Deborah Kobewka, managing director of HCUK, introduced NHS medical system of UK and its operation conditions to the team members. She described HCUK as a government interface between UK and foreign medical partners, welcoming cooperation between West China Hospital and famous UK organizations like Cambridge UKeMED. The delegation also visited four private high-end UK medical centers at Harley Street. The team led by Director Li Weimin and executive vice director Wan Xuehong met representatives from some departments of Hammersmith Hospital affiliated with Imperial College London, including Anesthesiology Department, Cardiac Surgery Department, and Health Care Division, and expressed their thanks for multiple training sessions provided by the hospital for the medical team of West China Hospital.

On July 14, the delegation met Ms. Betty Yue, supervisor of Continuing Education & Training Center of Imperial College London, and Professor Desmond Johnston, vice president of Medicine School. Both parties achieved deeper understanding of each other, which laid a solid foundation for future cooperation.

This visit to University of Liverpool, Cambridge University Hospitals, and Imperial College London improved mutual understanding between West China Hospital and advanced academic research institutes in UK, and was concluded with preliminary cooperation plans regarding medical education and research. Such cooperation will enable West China Hospital to better build an international brand and integrate international resources, thus greatly promoting internationalization process of West China Hospital.

View original content with multimedia:http://www.prnewswire.com/news-releases/a-delegation-led-by-director-li-weimin-of-west-china-hospital-sichuan-university-visited-the-uk-300498107.html

PRNews

Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®

By controlling dangerous inflammation, CytoSorb® is enabling superior outcomes in critically-ill patients, with reduced overall costs of intensive care in its sights

LONDON, Aug. 2, 2017 /PRNewswire/ — Based on its recent analysis of the blood purification market, Frost & Sullivan recognizes CytoSorbents Corporation with the 2017 Global Frost & Sullivan Award for Product Leadership. CytoSorbents’ deceptively simple yet powerful blood purification therapy, CytoSorb®, helps critical care physicians and heart surgeons control deadly inflammation in their patients. CytoSorb® actively reduces circulating cytokines, toxins, and other substances in blood that feed and perpetuate uncontrolled inflammation in a diverse set of medical emergencies such as sepsis, infection, trauma, cardiac surgery, and liver failure. Its ultimate aim is to prevent a patient from being killed by his or her own out-of-control immune response.

“There were many factors that led to our selection of CytoSorb® for this year’s Global Product Leadership Award,” said Frost & Sullivan Research Analyst Aish Vivek. “Among the most important was the recognition that this innovative product is surprisingly well-positioned to help solve two long-standing, difficult, and tightly linked fundamental problems with hospital medicine today. These include the high rates of death from common critical illnesses such as sepsis that have no approved treatment, and the resulting staggering costs and losses in critical care that are financially crippling hospital networks and healthcare systems throughout the world.”

“Further strengthening CytoSorb’s position is the scarcity of viable competition in the lucrative and vast global critical care and cardiac surgery markets, the strong physician usage and revenue growth, and the external validation from well-respected industry partners, such as Fresenius Medical Care and Terumo Cardiovascular, and government funding agencies.  As a high margin, single-use product that works with existing blood pumps in hospitals, CytoSorb® also has an attractive business model that is expected to drive early and significant profitability of the company.”

“CytoSorb® has taken blood purification as a means to control inflammation to the next level, with its patented blood compatible, porous polymer bead technology,” concluded Aish Vivek. “This best-of-breed solution is approved in the European Union and has been used in more than 23,000 treatments to help save many lives across 44 countries.  As the clinical experience and scientific publications continue to grow, we predict that CytoSorbents, through CytoSorb®, will solidify its leadership in critical care and cardiac surgery, with expansion into other promising fields such as cancer immunotherapy, and treatment of chronic illness. We are also excited to follow along as CytoSorbents initiates a registration trial later this year that targets U.S. FDA approval.”

Overall, for positioning itself strongly with its CytoSorb® therapy and serving a wide array of applications, Frost & Sullivan is pleased to present CytoSorbents with the 2017 Global Frost & Sullivan Award for Product Leadership in the blood purification market.

Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality, gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About CytoSorbents Corporation

CytoSorbents Corporation (NASDAQ: CTSO) is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in 44 countries worldwide, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, complications of surgery, cancer immunotherapy, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval.  CytoSorb® has been used safely in more than 23,000 human treatments to date.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding in excess of $19 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents, multiple international patents, and many applications pending worldwide.  Products under development include CytoSorb-XL™, HemoDefend™, VetResQ™, ContrastSorb, DrugSorb, and others.  Visit www.cytosorbents.com and www.cytosorb.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Aish Vivekanandan
Phone: 210-477-8495
Email: aish.vivekanadan@frost.com

PRNews

Frost & Sullivan Commends Credence ID’s Rollout of CredenceTAB(TM), a Biometric Tool that Combines Document Reading and Biometric Enrollment and Verification in a Portable Device

Credence ID’s unique product suite offers convenience, portability, and customization to satisfy a wide range of identification projects

SANTA CLARA, California, Aug. 1, 2017 /PRNewswire/ — Based on its recent analysis of the mobile biometrics and credential reading market, Frost & Sullivan announced today the recognition of Credence ID for its 2017 Global New Product Innovation Award. In May 2017, Credence ID introduced CredenceTAB, a 10-inch tablet that combines the functionalities of an eDocument reader, high-resolution camera, fingerprint scanner, machine readable zone (MRZ), and a smart card reader in a single handheld device for the biometric ID industry. The solution was developed in line with the company’s vision to deliver enrollment and identification solutions to facilitate programs that provide benefits to underdeveloped and under-documented populations worldwide. With its portability and connectivity through Wi-Fi, Bluetooth, and mobile networks, the CredenceTAB greatly aids the national ID programs of various governments.

CredenceTAB and its related software development kit (SDK) enjoy a plethora of application opportunities across both government and commercial applications. The solution’s fingerprint scanner uses a FAP-30 sensor that enables fingerprint capture in all lighting conditions. The sensor is based on a light emitting sensor (LES) optical technology, which captures the optical image of the fingerprint on a thin film transistor to generate a PIV class fingerprint image. Additionally, Credence ID supports facial recognition and barcode reading by embedding two high-resolution cameras in CredenceTAB.

“CredenceTAB provides broad flexibility to its customers through its multi-functional, portable, battery-powered solution,” said Frost & Sullivan Industry Analyst Ram Ravi. “Credence ID has leveraged years of experience in designing, engineering, and manufacturing mobile identification devices to create this purpose-built, competitively-priced product. Furthermore, as they are built on an open development platform, Credence ID’s products are configurable and aid complete customization of the biometric device.”

Significantly, Credence ID’s main biometric solutions, Trident®, CredenceONE™, CredenceONE-MRZ™, and CredenceTAB, boast user friendliness and multi-modal product features that far exceed the accuracy and speed of the latest consumer devices.

  • Trident is a tri-biometric platform encompassing a dual-iris scanner, an industry-leading FAP 45 fingerprint sensor, and a high-resolution camera to capture facial images. The solution employs a long-life lithium ion battery that extends duty cycles.
  • CredenceONE’s robust, compact mobile chipset enables multiple identity-based solutions by using three sensors for scanning smart cards, faces, and fingerprints.
  • CredenceONE-MRZ and CredenceTAB feature four sensors on-board. Additionally, these solutions have a completely integrated smart card reader system (contact and contactless), a MRZ scanner, a facial recognition camera, and an enterprise-class fingerprint sensor.

Credence ID’s product design strategy has augmented its success, particularly in government and civil ID programs, which, in turn, has eased the company’s entry into commercial Know your Customer (KYC) applications.

“Credence ID has established an impressive clientele of top-tier value-added resellers and solution providers that build, manage, and support government and civil ID programs and applications,” noted Ravi. “By using the Android OS, Credence ID endows its partners with the freedom to create an array of intuitive applications. Its knack for industrial design and innovation, backed by continuous product improvement and customer support, has established it as a trustworthy supplier of mobile biometric solutions to government and civil ID applications.”

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased return on investment (ROI) it provides to customers, which, in turn, raises customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Credence ID

Headquartered in Emeryville, California, Credence ID was formed by like-minded business leaders focused on providing non-reputable biometric identities, especially to marginalized populations. The company’s personnel include experts in the field of biometrics and advanced mobile technologies. The Credence ID product line offers mobile biometric solutions and credential reading. With the industry at the crossroads of mobile and biometric technologies, Credence ID’s product line is perfectly aligned to capitalize on this trend. The company’s product suite includes features such as lower costs, better performance, advanced ergonomics, and complete customization.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Estefany Ariza
P: 210.477.8469
E: estefany.ariza@frost.com

Photo – https://mma.prnewswire.com/media/540828/Credence_Award_Logo.jpg

PRNews

Verdezyne Groundbreaking Ceremony in Malaysia Commemorates Initiation Of The World’s First Biobased DDDA Plant

-VerdePalm Plant to Use Sustainable Palm-based Materials to Manufacture Components of FerroShield™ Dibasic Acid Mixture for Superior Corrosion Inhibition

CARLSBAD, Calif. and KUALA LUMPUR, Malaysia, July 31, 2017 /PRNewswire/ — Verdezyne Inc., a synthetic biology company producing biobased chemicals, announced today that a groundbreaking ceremony was held on July 30th for its VerdePalm plant, Verdezyne’s first commercial-scale renewable chemicals manufacturing facility, at the Bio-XCell premier biotechnology and ecosystem park in Nusajaya, Iskandar, in southern Malaysia. The new facility is designed to produce biobased long chain diacids via fermentation of Verdezyne’s proprietary yeast, which has been engineered to use non-food biomass to produce high value chemicals.  The first product produced at VerdePalm will be dodecanedioic acid (DDDA), a 12-carbon diacid that is a component of many consumer products currently made from petroleum.  DDDA is a main building block of FerroShield™, Verdezyne’s nitrate-free dibasic acid mixture used in a variety of corrosion inhibitor applications.

The groundbreaking ceremony for the VerdePalm plant was co-hosted by Chad Waite, Chairman of the Verdezyne Board of Directors, and YBhg. Tan Sri Dato‘ Abdul Ghani Othman, Chairman of the Board of Sime Darby Berhad, the largest investor in Verdezyne Inc.  Attendees included Malaysian dignitaries and representatives from Verdezyne’s partners, Bio-XCell Malaysia and the Malaysian Biotechnology Corporation.  The Guest of Honor, YAB Dato’ Mohamed Khaled Nordin, Chief Minister of Johor, presented the Officiating Speech.

The VerdePalm plant is expected to be completed in 12-18 months.  VerdePalm will be the world’s first biobased plant for DDDA production.  “Importantly, the starting yeast will be made from the spent biomass that results from palm oil processing,” Waite stated.  “Crude palm oil and palm byproducts, as well as other plant-based raw materials, will be used to produce approximately 6,000 metric tons of industrial grade DDDA each year.  Verdezyne’s technology will enable a very low-value by-product of palm oil processing to become a high-value “green” product that reduces the use of petroleum.” 

“We are excited that a product made by Verdezyne and our Malaysian partners will be shipped around the world to be used as an alternative to the typical petroleum-derived intermediate chemicals,” said E. William Radany, Ph.D., President and CEO of Verdezyne. “The VerdePalm plant is part of our comprehensive strategy of expansion into Asia, and represents a major step toward our goal of replacing petroleum-derived chemicals with renewable drop-in replacements,” he noted.

“Malaysia is proud to host Verdezyne’s first commercial manufacturing plant, which is located at the Malaysin Bio-XCell park.  I believe the eco-system provided by the park will be an excellent fit for the VerdePalm facility.  Malaysia will continue to commit to the ongoing advancement of biotechnology in the country.  The groundbreaking ceremony signifies Verdezyne’s readiness to work with Malaysia and marks another milestone in our quest to add value to the palm industry using biotechnology as a catalyst,” said Zainal Azman B. Abu Kasim, Senior Vice President of BioIndustrials, Bioeconomy Corporation in Malaysia.

DDDA is a key component of FerroShield, which can be used in numerous corrosion inhibitor applications including metalworking fluids, engine coolants, metal cleaners, die cast release agents, and aqueous hydraulic fluids.  “Marketing of FerroShield was launched in February of this year,” Dr. Radany added. “The rust inhibition industry is in need of a high-performing dibasic acid mixture that can be easily incorporated into existing customer formulas.  We foresee strong demand for FerroShield in a number of countries in Asia and Europe, as well as in the U.S. and Canada.”

About Verdezyne 
Verdezyne is a synthetic biology company offering biobased chemicals manufactured via fermentation of its proprietary yeast cells. The company has two commercial products, BIOLON™ DDDA (dodecanedioic acid) and FerroShield™ dibasic acid mixture.  Current investors in Verdezyne include BP Ventures, DSM Venturing B.V., OVP Venture Partners, Monitor Ventures, and Sime Darby. For more information, visit www.verdezyne.com or connect with the company on Twitter, LinkedIn or Facebook.

For samples, orders or more information about Verdezyne’s FerroShield, please contact:

Verdezyne Media Contact:

Jenna Ngian 
Vice President, Global Sales and Marketing
JNgian@Verdezyne.com  
+1-760-707-5288 

Logo – https://mma.prnewswire.com/media/414701/Verdezyne___Logo.jpg

PRNews

Redleaf Forming a “miniature United Nations”

SHANGHAI, July 28, 2017 /PRNewswire/ — Shanghai Redleaf International Women’s and Children’s Hospital launched their fourth anniversary celebrations with a ceremony at 11am Sunday in the main lobby of the hospital. Redleaf babies of various nationalities came together to celebrate the birthday of those babies born in July, as well as the birthday of Redleaf. The Hospital donated an additional one million yuan to the existing Redleaf Award created by the Shanghai Association of Medical and Hygiene Development Funds, to support and reward excellent gynecologists, pediatricians and related medical professionals in Shanghai. The hospital also presented a donation of one hundred thousand yuan to Hong Kong charity, Principal Chan’s Free Tutoring, which provides free tutoring and other education assistance to children of low-income families in Hong Kong. Taiwanese musical genius, deaf pianist Hsu Che-cheng, otherwise known as Modern Day Beethoven, played and sang such songs as “Qin ai de Xiaohai”, to express the sacredness of human life and focus on children’s development. Carnival activities were held in the afternoon, and all proceeds of a garden sale were donated to the Shanghai Song Qingling Foundation.


Shanghai Redleaf International Women’s and Children’s Hospital, forming a “Miniature United Nations”

As a medical institution focused on the needs of the expatriate community, Shanghai Redleaf International Women’s and Children’s Hospital has seen the birth of over 1800 infants of varying races and nationalities, resembling a miniature United Nations. The 130 medical professionals at Redleaf hail from such countries and regions as the USA, the Philippines and Taiwan, and provide Chinese and English bilingual services to Redleaf families. This has led parents of over one hundred nationalities to choose Redleaf, creating a perfect example of non-governmental diplomacy, bringing people of different backgrounds closer together.

This series of events was hosted by renowned media personality Yang Jinlin. Reflecting the spirit of the medical profession, doctors and families at Redleaf have developed strong bonds of mutual trust and support. In the case of a mother whose womb had not fully developed and whose foreign-national baby was born prematurely at only 1.810kg with extremely unstable blood sugar levels, they were able to nurse the infant back from the brink and save its life. Dr Carenia Kuan from the USA has 30 years experience as a pediatrician. Her Pediatrics and New Birth Pediatrics teams at Redleaf share a wealth of experience as well as being very international.

Redleaf also offers highly personalised post-natal service, including comprehensive infant care as well as care and support for new mothers. Flower arrangements, bookmark decoration and handcraft discussions are some of the activities that await new mothers as they enjoy their month’s rest, which is a kind of postnatal care in China. Attention to every detail ensures that new families find the feeling of a real home at Redleaf.

A lot has changed in four years as Redleaf has constantly improved and sharpened every aspect of its service, all the while adhering to its mission to lead the way in the development of the industry and provide the highest quality in medical service. Redleaf stands ready to face future growth alongside all the Redleaf families.

More about Redleaf:

Redleaf is a specialist hospital created to the global professional risk management standard DNV.GL (Det Norske Veritas), with an international team providing top-quality medical service to women and children. Gynecology, Obstetrics, Mammography, Newborn Pediatrics, Pediatrics, Children’s General Practice, Post-Natal Care, and Early Childhood Development form the core activities of Redleaf, while the addition of cosmetic and corrective procedures ensure the Redleaf is a comprehensive medical facility for new mothers and newborn infants alike. There are six LDR (labour, delivery, recovery) birthing suites, including two with water birth facilities. In addition there are a further twelve LDRP (labour, delivery, recovery, post-natal) combined birthing suites.

In terms of facility management, Redleaf leads the way in China by making use of the high-quality, paperless, international-standard management system SAP. Technological synergies and smart IT solutions ensure a better standard of service to Redleaf families.

For more information about Redleaf, please read http://www.redleafhospital.com/

For further consultation or inquiry, please contact:

Address: No.1209 Middle Huaihai Rd, Xu hui District, Shanghai
 24 hrs Hotline: +86-21-6196-3333
 General Tel: +86-21-6196-1133
Mailbox: cs@redleafhospital.com

View original content with multimedia:http://www.prnewswire.com/news-releases/redleaf-forming-a-miniature-united-nations-300495105.html

PRNews

OrthoAccel Technologies, Inc. Names Orthodontic and Dental Industry Executive David Josza as CEO

HOUSTON, July 26, 2017 /PRNewswire/ — OrthoAccel® Technologies, Inc. announces that its board of directors has named David Josza, an orthodontic and dental industry senior executive with more than 25 years of experience, as CEO effective August 1, 2017. A privately owned medical technology start-up, OrthoAccel recently launched its third-generation vibratory orthodontic device AcceleDent® Optima™ that enables orthodontists to achieve more predictable outcomes. AcceleDent Optima is an FDA-cleared, Class II medical device that is clinically shown in randomized control trials to speed up orthodontic treatment by as much as 50 percent while reducing discomfort by up to 71 percent during treatment.

“OrthoAccel is a market leader in accelerated orthodontic technology and I am delighted to lead the company’s next phase of growth and innovation,” said Josza. “This is an exciting stage in OrthoAccel’s trajectory and, based on the feedback of orthodontists and patients who have experienced the new AcceleDent Optima, there is significant opportunity for growth ahead for this best-in-class treatment technology.”

Josza most recently served as corporate vice president and general manager for Zimmer Biomet Dental, a leading global manufacturer of musculoskeletal devices. He joined Zimmer in 2015 when the company acquired his previous firm, Biomet, Inc., and Josza was tapped to lead the complex acquisition integration. Among his accomplishments, he successfully implemented synergistic cost-saving initiatives and cross-selling opportunities that yielded significant profit increases and growth.

Prior to the acquisition, Josza had a 14-year career at Biomet 3i, a global implant and oral reconstructive supplier, most recently serving as vice president of the Americas. As a member of the executive board, he was responsible for developing and delivering the company’s annual strategic plan.

Additional accomplishments at Biomet included developing and leading a variety of significant revenue growth initiatives, including capturing the market leader position in Latin America. Another key accomplishment was the commercialization of a new digital product line, with a specialized sales team and a technical service support function that grew incremental revenue by $2 million in its first year.

In addition to his leadership roles at Zimmer and Biomet, Josza’s in-depth experience includes previous business development, strategic planning and management responsibilities at Henry Schein, Inc. and Stryker Corporation.  

“We are excited to welcome David and recognize that his in-depth experience in dental and medical industries, combined with his many successes as a strategist and business developer, provide an excellent leadership platform for his role at OrthoAccel Technologies,” said Brian R. Smith, chairman of OrthoAccel’s board of directors and managing director of S3Ventures.

The leader in accelerated orthodontics, OrthoAccel has received numerous business and medical design awards that reflect the company’s success in commercializing its patented SoftPulse Technology® for clinical application. AcceleDent has been recognized as the preferred accelerated orthodontic treatment solution by orthodontists participating in surveys conducted by industry journals Orthotown and the Journal of Clinical Orthodontics.

For more information about OrthoAccel and the company’s innovative orthodontic solutions, visit AcceleDent.com.

About OrthoAccel® Technologies, Inc.
OrthoAccel® Technologies, Inc. is a privately owned medical device company engaged in the creation, manufacturing, marketing and sales of innovative solutions that enhance dental care and orthodontic treatment. Among the company’s innovations is AcceleDent® Optima™, an FDA-cleared, Class II medical device that employs patented SoftPulse Technology® that is demonstrated to speed up bone remodeling. These safe and gentle vibrations accelerate tooth movement by as much as 50 percent and reduce discomfort associated with orthodontic treatment by up to 71 percent. Leading orthodontists from around the world report increased mechanical efficiency with orthodontic appliances and improved predictability of clinical outcomes with AcceleDent.  OrthoAccel, the Leader in Accelerated Orthodontics, is ranked on Deloitte’s 2016 Technology Fast 500 as one of the fastest growing companies in North America. OrthoAccel is based in Houston, Texas and maintains a global presence through its EMEA office in Essen, Germany. To learn more about OrthoAccel’s focus on improving the journey to healthy, beautiful smiles, visit AcceleDent.com.

Source: OrthoAccel Technologies, Inc.

PRNews

Frost & Sullivan Acclaims CGI’s Advanced Genomic & Biomarker Technologies That Drive Industry Innovation in Support of Precision Cancer Treatment

CGI’s technologies provide valuable insights across cancer diagnostics through the accurate and sensitive quantitation of clinically relevant genomic signatures & biomarkers from both blood and tissue samples

SANTA CLARA, California, July 26, 2017 /PRNewswire/ — Based on its recent analysis of the precision oncology industry, Frost & Sullivan recognizes Cancer Genetics, Inc. (CGI or the Company) with the 2017 North American Frost & Sullivan Award for Technology Innovation. CGI’s leading-edge technology platforms and comprehensive menu of diagnostic services enhance precision oncology by enabling earlier cancer detection, improving treatment management, and aiding the development of novel cancer therapies. The Company’s genomic products and services not only present diagnostic, prognostic, and theranostic information for routine clinical care, but also facilitate and accelerate drug development programs seeking to deliver targeted, more effective and safer drugs to market more quickly. With its comprehensive suite of both off-the-shelf and proprietary tests, technology-agnostic approach, global infrastructure, and extensive research collaborations, CGI is at the forefront of enabling precision medicine in oncology globally, from bench to bedside.

“CGI has a wide variety of assays for genomic and immuno-oncology related biomarkers, applicable across several therapeutic areas, including hematological malignancies, solid tumors, and hereditary cancers,” said Frost & Sullivan Research Analyst Vandana Iyer. “The Company offers a broad range of laboratory services that provide critical genomic and biomarker information for patient care and for clinical trials being performed by biotech and pharmaceutical companies. CGI’s recent launches of cutting edge tests, its ability to partner with innovative companies, and its extensive research collaborations with leading academic institutions and cancer centers are a testament to the value and depth of CGI’s commitment to driving industry innovation.”

Some of CGI’s prominent and recently launched technologies include:

  • Complete::IO™ is a unique and in-depth flow cytometry panel supporting informed therapeutic decisions and assessment of potential toxicities for novel immuno-oncology (IO) therapies in blood cancers and solid tumors.
  • Focus::Oncomine™ is capable of simultaneously testing DNA and RNA, enabling the detection of various types of genomic alterations in a single workflow that requires minimal sample quantities and boasts a rapid turnaround time. The Focus::Oncomine™ assay can detect thousands of clinically and pharmacologically relevant biomarkers in solid tumors, making it a valuable tool for clinicians and biopharma.
  • Focus::Lymphoma™ is the most comprehensive next generation sequencing (NGS) panel for B-cell lymphomas in the field.  Focus::Lymphoma™, sequences 220 clinically-actionable genes, allowing clinicians to determine the most effective treatment management for patients. Focus::Lymphoma™ is also offered to biotech and pharmaceutical companies to power efficient clinical trials focused on B-cell lymphomas.
  • Focus::Renal™ is a highly-sensitive NGS panel that provides thorough information for the diagnosis, prognosis and therapy selection in renal cancers.  In a single test, Focus::Renal™ is able to detect mutations in 76 renal cancer-related genes, as well as genome-wide copy number changes, and critical single nucleotide polymorphisms (SNPs). Focus::Renal™ is the only NGS panel of its type, as it is disease-focused, and has been developed through collaboration with leading cancer centers and academic institutions, including MSKCC, Cleveland Clinic, Huntsman Cancer Center at University of Utah, and University Hospital of Paris.
  • Liquid::Lung-cfDNA™ is a CLIA-validated, multi-gene NGS panel for lung cancer liquid biopsies. The test can detect lung tumor-derived cell-free DNA (cfDNA) obtained from a single blood draw, and analyzes frequently-mutated SNPs and short indels in 11 genes with significant clinical relevance to non-small cell lung cancer (NSCLC). This groundbreaking assay is highly sensitive, with a limit of detection (LOD) as low as 0.05% or 1 mutant copy of DNA in a background of 2,000 wild-type copies of DNA.
  • Focus::HERSite™ is a hereditary cancer test that focuses on breast and ovarian cancers. The test analyzes the 16 genes most commonly associated with breast and ovarian cancers and provides in-depth coverage of BRCA1 and BRCA2.
  • Oncomine Dx Target Test is the first NGS-based companion diagnostic (CDx) test that simultaneously screens tumor samples for biomarkers associated with 3 FDA-approved therapies for non-small cell lung cancer (NSCLC). CGI is one of the first laboratories, and one of only three in the United States, to offer the Oncomine Dx Target Test.

CGI has established a global footprint with a presence in the United States, India, and China. The Company’s infrastructure, which has been developed through strategic acquisitions, and its unique business model, which incorporates routine clinical testing for cancer patients and fee-for-service solutions for biotech and pharmaceutical companies, have positioned it uniquely for diversified growth and access to the oncology community. These factors have supported the Company’s successful development of a durable business model through which to commercialize its oncology programs and testing capabilities.

“CGI is a technology-agnostic company with comprehensive diagnostic capabilities utilizing various platforms, including next generation sequencing, fluorescence in situ hybridization, immunohistochemistry, microarrays, RT-PCR, and flow cytometry. The Company boasts full NGS capabilities with both Illumina and Thermo Fisher platforms, offering a mix of proprietary panels and off-the-shelf assays,” noted Iyer. “CGI has several ongoing research collaborations with leading oncologists and cancer centers in both solid tumors and hematological malignancies, including kidney cancer, leukemia, non-Hodgkin’s lymphoma, and HPV-associated cancers. The Company constantly strives for diversity and innovation, and has successfully achieved a balance between the two.”

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impact both the functionality and the customer value of new products and applications. The award lauds the high R&D spend towards innovation, its relevance to the industry, and the positive impact on brand perception.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

ABOUT CANCER GENETICS, INC.

Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at:

Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Media Contact:
Panna Sharma
Cancer Genetics, Inc.
Tel: 201-528-9200
Email: panna.sharma@cgix.com

Investor Relations Contact:
Richard Moyer
Cameron Associates
535 Fifth Ave., New York, NY 10017
Tel: 212-554-5466
Email: richard@cameronassoc.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Andrea Steinman
P: 210.477.8425
F: 210.348.1003
E: andrea.steinman@frost.com

PRNews

Survey Finds 68% of Healthcare Respondents Not Familiar with Indoor Location Technologies

LONDON, July 26, 2017 /PRNewswire/ — In a recent B2B technology survey of 455 U.S.-based companies across nine verticals, ABI Research finds that only 32% of respondents are familiar with indoor location technologies and their cost saving benefits. The findings show a disconnect between the healthcare industry’s evident need for an asset tracking solution and their willingness to implement one. Only 2% of healthcare respondents had plans to deploy an indoor location solution within the next twelve months.

“The healthcare industry could see significant returns on investment by tracking assets such as infusion pumps across facilities, especially as medical devices become increasingly advanced and more expensive,” says Samuel McLaughlin, Research Analyst at ABI Research. “There is reluctance within healthcare to deploy asset tracking solutions, despite the potential to save both money and lives. Installation expenses can be high if the solution is not compatible with the hospital’s already-existing network infrastructure and regulations. Indoor location vendors must demonstrate they can offer standards-based systems which can support interoperability features, resulting in easier installation and reduced upfront costs.”

Multiple industry sources estimate that between 10% and 20% of hospital inventory is stolen or lost each year.  This could be partly attributed to healthcare personnel favoring certain equipment and keeping it in areas where only they can access it, rather than where it should be stored. Typical assets that might be tracked in a hospital include ventilators, dialysis machines, heart rate monitors, wheelchairs, and IV pumps. One hospital alone has estimated the yearly cost of replacing IV pumps at US$70k.

Adoption of new and emerging technologies has been traditionally slower in healthcare compared to other verticals, often due to funding issues and cost-saving measures at a government or organizational level. “Recent breaches in security in healthcare systems due to antiquated systems across the world should serve as a wake-up call in hospital organizations to embrace emerging technologies sooner rather than later,” concludes McLaughlin.

These findings are from ABI Research’s Industry Survey: Transformative Technology Adoption and Attitudes report. This report is part of the company’s Location Technologies research service, which includes research, data, and analyst insights.

About ABI Research

ABI Research stands at the forefront of technology market research, providing business leaders with comprehensive research and consulting services to help them implement informed, transformative technology decisions. Founded more than 25 years ago, the company’s global team of senior and long-tenured analysts delivers deep market data forecasts, analyses, and teardown services. ABI Research is an industry pioneer, proactively uncovering ground-breaking business cycles and publishing research 18 to 36 months in advance of other organizations. For more information, visit www.abiresearch.com.

Contact Info: 

Americas                               

EMEA/APAC

Deborah Petrara                       

Denise Duffy

Tel: +1.516.624.2558                 

Tel: +44.203.326.0142

pr@abiresearch.com                  

duffy@abiresearch.com
Exit mobile version